Health and Healthcare
Why the Top Aerie Pharma Analyst Sees It Rising Even More
Published:
Last Updated:
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) saw its shares skyrocket Thursday following the release of positive results from a recent study. Analysts are pouring into the stock and issuing updated calls. 24/7 Wall St. choose to highlight Canaccord Genuity and its take on Aerie.
The company reported the successful results of its second Phase 3 trial for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa compared to timolol, the most widely used comparator.
Some clinicians have been waiting for an IOP-lowering product that specifically targets the diseased tissue. However, currently no treatments in the market have this unique function.
Canaccord Genuity analyst Corey Davis has a Buy rating and increased his price target to $44 from $40. He also said in the report:
After much anticipation, Aerie announced positive data from Rocket 2, refuting Street musings that it dredged Rocket 1 to make Rhopressa seem more efficacious. While it nailed the reconfigured primary endpoint, there is still more analysis to come. But it’s now very clear that the drug has clinically meaningful activity in glaucoma and in our opinion is very approvable. Furthermore, we have already seen enough to project that Rhopressa will have a significant place among glaucoma patients with lower starting IOP.
ALSO READ: 4 Safe High-Yield Dividend Stocks to Buy for Ongoing Volatility
The firm picked Rhopressa as a winner for a few reasons:
Canaccord Genuity believes the next catalyst will be in mid-2016 with results from Rocket 4 and the first Roclatan.
Other analysts that weighed in on Aerie had this to say on Thursday:
As a result of this resounding win, and analysts’ confidence in the approvability of Rhopressa, many firms raised their price targets.
ALSO READ: 8 Buybacks and Dividends Just Too Big to Ignore
Shares of Aerie were up nearly 68% at $30.19 on Thursday afternoon. The stock has a consensus analyst price target of $32.86 and a 52-week trading range of $8.84 to $30.15.
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.